Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma

SIMPLE SUMMARY: In patients with mantle cell lymphoma (MCL), an effective and safe high-dose chemotherapy regimen as consolidation of first-line treatment prior to ASCT is a matter of ongoing exploration due to unsatisfying outcomes with a relevant rate of relapse in the following course of disease....

Descripción completa

Detalles Bibliográficos
Autores principales: Huwyler, Fabrizio, Kunz, Rebekka, Bacher, Ulrike, Hoffmann, Michèle, Novak, Urban, Daskalakis, Michael, Banz, Yara, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093600/
https://www.ncbi.nlm.nih.gov/pubmed/37046753
http://dx.doi.org/10.3390/cancers15072091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093600/
https://www.ncbi.nlm.nih.gov/pubmed/37046753
http://dx.doi.org/10.3390/cancers15072091

Ejemplares similares